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Abstract 
Background: Type 2 diabetes mellitus (DM) and hypertension are worldwide epidemic. Colorectal 
cancer (CRC) is the most prevalent gastrointestinal cancer in Iran. Prevalence of type 2 diabetes mellitus 
and hypertension in the patients with colorectal cancer had not reported in Iran, before this study.  
Methods: Overall, 2570 individual-year follow-ups were conducted for 1127 patients with colorectal 
cancer. For diagnosis of type 2 diabetes mellitus, fasting blood sugar and glycosylated hemoglobin 
tests were used and for that of hypertension, blood pressure was measured in two turns. The 
descriptive indices were calculated and the mean and median survivals, from colorectal cancer 
diagnosis time, were calculated using survival analysis and the comparison among survival times was 
done through log-rank test. Stata12 software  was used for data analysis. 
Findings: The prevalences of hypertension and type 2 diabetes mellitus in the patients with colorectal 
cancer were 13.38% (95% CI: 11.1-15.8) and 8.69% (95% CI: 7.0-10.7), respectively. Median 
survival time in patients with hypertension and diabetes mellitus were 8.52 and 4.90 years, 
respectively. According to log-rank test, no significant difference was observed between the survival 
time of patients with colorectal cancer suffering from hypertension and type 2 diabetes mellitus. 
Conclusion: The obtained findings in this study indicate that survival time in patients with type 2 
diabetes mellitus is less than those with hypertension; but two metabolic diseases have same effect on 
survival rate of the patients with colorectal cancer. 
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